Views & Analysis | Perspectives on pharma industry issues

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

R&D

Closed & Collaborative – January to February 2026

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

Patients

European Health Data Space (EHDS) update: what this means fo...

The proposed EHDS Regulation1 (Proposal), introduced in May 2022 by the European Commission (EC), aims to reform the “situation of fragmentation” that depicts th

R&D

With landmark approval, spotlight on cryogenic logistics int...

The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world.

R&D

How decentralised storage networks can change the game for t...

The way pharmaceutical companies manage data carries inherent risks, as exemplified by the constant scandals about

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Digital

Sponsored

STEM AI: A new lens on data-led field team performance

The relationship between pharmaceutical field teams and healthcare professionals (HCPs) is evolving rapidly.

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology